<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556035</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2011/28</org_study_id>
    <nct_id>NCT01556035</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma</brief_title>
  <acronym>REV-LEG</acronym>
  <official_title>A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid®) in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) After First Line Treatment by Chemotherapy Plus Rituximab for the French Study Group of Cutaneous Lymphoma (GFELC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In spite of high initial response rate after a first line treatment by R-polychemotherapy,&#xD;
      cutaneous but also extra-cutaneous recurrences occur after 2 years in about half of the&#xD;
      patients with PCBCL-LT. Thereafter there is no consensus concerning patients care:&#xD;
      radiotherapy has only a palliative effect, advanced age often limits using more aggressive&#xD;
      chemotherapies and no treatment has demonstrated a prolonged efficacy in these relapsing&#xD;
      cases. Therefore new alternatives therapeutic options are needed. Lenalidomide has an&#xD;
      antineoplastic pro-apoptotic effect but also immunomodulatory, and antiangiogenic properties.&#xD;
      Preliminary results suggest its efficacy in relapsing or refractory diffuse large B-cells&#xD;
      lymphomas, especially of nongerminal cells phenotype. By analogy with these results,&#xD;
      lenalidomide appears as an attractive candidate in PCLBCL-LT, more specially as it has a&#xD;
      manageable toxicity even in advanced age patients.&#xD;
&#xD;
      If the lenalidomide efficacy is confirmed in relapsing PCLBCL-LT, this will plead its&#xD;
      evaluation as maintenance therapy after R-chemotherapy in order to avoid recurrences.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess benefit and safety of lenalidomide in patients with refractory or relapsing primary&#xD;
      cutaneous large B-cell lymphoma leg type (PCBCL-LT) after a first line treatment by Rituximab&#xD;
      and polychemotherapy. The primary endpoint is overall response rate (complete response and&#xD;
      partial response) at 6 months. Response will be assessed according to clinical and isotopic&#xD;
      criteria.&#xD;
&#xD;
      Optional biological study:&#xD;
&#xD;
      A biological collection (skin and blood samples) will be established. Predictive biological&#xD;
      markers of response or of aggressiveness and resistance to the treatment will be investigated&#xD;
      on the skin biopsies by phenotypic and genetic analyses. The recent discovery of BLIMP1&#xD;
      inactivation or deletion at 6q21 in activated B-cell like type of diffuse large B-cell&#xD;
      systemic lymphoma points to the need of both a global genetic analysis by Array-CGH with&#xD;
      Single Nucleotide Polymorphism study and a specific investigations of the status of genes&#xD;
      such as CDKN2A, BCL2, BCL6 and BLIMP1 by FISH analysis and/or gene dosage. Xenograft will be&#xD;
      performed from skin biopsies in order to develop animal models for PCLBCL-LT.&#xD;
&#xD;
      Lenalidomide stimulates NK cells immunity and enhances anti-tumor responses. It also seems to&#xD;
      modify the phenotype of NK cells through a decrease of the expression of Killer cell&#xD;
      Immunoglobulin-like Receptors and NKp46. The expression of the NK receptors on blood cells&#xD;
      will be analyzed in order to evidence modifications of the phenotypical and functional&#xD;
      changes under treatment, and to search for a correlation with the clinical response to the&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (complete response CR and partial response PR) at 6 months</measure>
    <time_frame>6 months after study treatment start</time_frame>
    <description>Response will be assessed according to clinical and isotopic criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (complete response CR and partial response PR) at 12 months</measure>
    <time_frame>12 months after study treatment start</time_frame>
    <description>Response will be assessed according to clinical and isotopic criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Time between the first PR and progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Time between the beginning of the treatment by lenalidomide and progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and disease specific survival</measure>
    <time_frame>Evrey 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : description of adverse events occured including grade based on CTCAE v4.0</measure>
    <time_frame>Monthly during treatment duration (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Every 2 months during treatment duration (up to 12 month)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)</condition>
  <arm_group>
    <arm_group_label>Lenalidomide treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression</description>
    <arm_group_label>Lenalidomide treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven Primary cutaneous large B-cell lymphoma leg-type&#xD;
&#xD;
          -  Clinically measurable skin involvement (T1-T3) or skin and nodal (N1-N3) involvement&#xD;
             measurable by PET-CT, corresponding to :&#xD;
&#xD;
        Relapse after initial complete response (CR) after R-polychemotherapy Or Partial response&#xD;
        or stable disease after R-polychemotherapy&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Skin biopsy performed at the inclusion on a skin tumor : new tumor in case of&#xD;
             relapsing PCLBCL-LT or initial skin tumor refractory to the previous treatment&#xD;
&#xD;
          -  Signed informed consent for clinical and biological analyses. The Lenalidomide&#xD;
             Information Sheet will be given to each patient receiving lenalidomide study therapy.&#xD;
             The patient must read this document prior to starting lenalidomide study treatment and&#xD;
             each time they receive a new supply of study drug.&#xD;
&#xD;
          -  Social security cover&#xD;
&#xD;
          -  Conditions of global RPP have to be fulfilled by all the patients&#xD;
&#xD;
          -  The Lenalidomide Education and Counseling Guidance Document must be completed and&#xD;
             signed by either a trained counselor or the Investigator at the participating clinical&#xD;
             center prior to each dispensing of lenalidomide study treatment. A copy of this&#xD;
             document must be maintained in the patient records.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system involvement (cerebral CT scan is performed at the inclusion)&#xD;
&#xD;
          -  One or more of the biological abnormalities :&#xD;
&#xD;
        Neutrophil count &lt; 1,500/mm3 ; Platelet count &lt; 60,000/mm3 ; Transaminases &gt; 5 x upper&#xD;
        limit of normal ; Total bilirubin &gt; 2.0 mg/dl (34 µmol/L)/ conjugated bilirubin&gt;0.8 mg/dL,&#xD;
        except of haemolytic anemia ; Creatinine clearance &lt; 50 mL /min ( measured or calculated&#xD;
        according to the method of Cockcroft-Gault)&#xD;
&#xD;
          -  Pregnant or lactating females, potentially childbearing females defined by sexually&#xD;
             mature female who: 1) has not undergone a hysterectomy (the surgical removal of the&#xD;
             uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not&#xD;
             been naturally postmenopausal (amenorrhea following cancer therapy does not rule out&#xD;
             childbearing potential) for at least 24 consecutive months (i.e., has had menses at&#xD;
             any time during the preceding 24 consecutive months.&#xD;
&#xD;
          -  Patients should not receive steroids continuously except for prednisone for tumoral&#xD;
             flare treatment&#xD;
&#xD;
          -  Uncontrolled infectious and thromboembolic diseases&#xD;
&#xD;
          -  Subjects not willing to take deep venous thrombosis prophylaxis&#xD;
&#xD;
          -  Prior history of malignancies unless the subject has been free of the disease for ≥5&#xD;
             years. Exceptions include basal cell skin carcinoma, carcinoma in situ of the cervix&#xD;
             or of the breast&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form&#xD;
&#xD;
          -  Known seropositive for or active viral infection with HIV, Hepatitis B and C virus.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection requiring parenteral antibiotics, uncontrolled diabetes mellitus as defined&#xD;
             by the investigator&#xD;
&#xD;
          -  Chronic symptomatic congestive heart failure (III or IV of the NYHA Classification for&#xD;
             Heart Disease)&#xD;
&#xD;
          -  Unstable angina pectoris, angioplasty or myocardial infarctions within 6 months&#xD;
&#xD;
          -  Clinically significant cardiac arrhythmia that is symptomatic or requires treatment,&#xD;
             or asymptomatic sustained ventricular tachycardia.&#xD;
&#xD;
          -  Prior ≥ Grade 3 allergic reaction/hypersensitivity or desquamative rash while taking&#xD;
             thalidomide&#xD;
&#xD;
          -  Any standard or experimental anti-cancer drug therapy or radiation within 3 weeks of&#xD;
             the initiation of study drug therapy.&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie BEYLOT-BARRY, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric FRISON, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unité de Soutien Méthodologique à la Recherche clinique et épidémiologique; University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens, Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon, Hôpital Saint-Jacques</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand, Estaing</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon, Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Groupe hospitalier l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP- Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Groupe hospitalier Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Groupe hospitalier Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Hôpital du Haut Lévèque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69450</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims, Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen, Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours- Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oncodermatology</keyword>
  <keyword>hematology</keyword>
  <keyword>cutaneous B cell lymphoma</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

